Species | Target name | Source | Bibliographic reference |
---|---|---|---|
Homo sapiens | tumor protein p53 | Starlite/ChEMBL | No references |
Homo sapiens | polymerase (DNA directed) iota | Starlite/ChEMBL | No references |
Species | Potential target | Known druggable target/s | Ortholog Group |
---|---|---|---|
Echinococcus granulosus | tumor protein p63 | Get druggable targets OG5_140038 | All targets in OG5_140038 |
Echinococcus multilocularis | tumor protein p63 | Get druggable targets OG5_140038 | All targets in OG5_140038 |
Species | Potential target | Raw | Global | Species |
---|---|---|---|---|
Mycobacterium leprae | Probable dihydroorotate dehydrogenase PyrD | 0.2655 | 1 | 0.5 |
Brugia malayi | Dihydroorotate dehydrogenase, mitochondrial precursor, putative | 0.2655 | 1 | 1 |
Wolbachia endosymbiont of Brugia malayi | dihydroorotate dehydrogenase 2 | 0.2655 | 1 | 0.5 |
Trichomonas vaginalis | dihydroorotate dehydrogenase, putative | 0.1037 | 0.3765 | 0.5 |
Plasmodium vivax | dihydroorotate dehydrogenase, mitochondrial precursor, putative | 0.2655 | 1 | 0.5 |
Plasmodium falciparum | dihydroorotate dehydrogenase | 0.2655 | 1 | 0.5 |
Trypanosoma cruzi | dihydroorotate dehydrogenase, putative | 0.2655 | 1 | 1 |
Mycobacterium ulcerans | dihydroorotate dehydrogenase 2 | 0.2655 | 1 | 0.5 |
Trichomonas vaginalis | dihydroorotate dehydrogenase, putative | 0.1037 | 0.3765 | 0.5 |
Onchocerca volvulus | 0.006 | 0 | 0.5 | |
Toxoplasma gondii | dihydroorotate dehydrogenase reveal, putative | 0.2655 | 1 | 0.5 |
Trichomonas vaginalis | dihydropyrimidine dehydrogenase, putative | 0.1037 | 0.3765 | 0.5 |
Trichomonas vaginalis | dihydroorotate dehydrogenase, putative | 0.1037 | 0.3765 | 0.5 |
Echinococcus multilocularis | dihydropyrimidine dehydrogenase (NADP+) | 0.1037 | 0.3765 | 1 |
Trichomonas vaginalis | dihydroorotate dehydrogenase, putative | 0.1037 | 0.3765 | 0.5 |
Echinococcus granulosus | dihydropyrimidine dehydrogenase NADP | 0.1037 | 0.3765 | 1 |
Echinococcus multilocularis | dihydropyrimidine dehydrogenase (NADP+) | 0.1037 | 0.3765 | 1 |
Trypanosoma cruzi | dihydroorotate dehydrogenase, putative | 0.2655 | 1 | 1 |
Schistosoma mansoni | dihydroorotate dehydrogenase | 0.2655 | 1 | 1 |
Trypanosoma cruzi | dihydroorotate dehydrogenase (fumarate), putative | 0.2655 | 1 | 1 |
Entamoeba histolytica | dihydropyrimidine dehydrogenase, putative | 0.1037 | 0.3765 | 0.5 |
Trichomonas vaginalis | dihydroorotate dehydrogenase, putative | 0.1037 | 0.3765 | 0.5 |
Leishmania major | dihydroorotate dehydrogenase | 0.2655 | 1 | 0.5 |
Trypanosoma brucei | dihydroorotate dehydrogenase (fumarate) | 0.2655 | 1 | 0.5 |
Mycobacterium tuberculosis | Probable dihydroorotate dehydrogenase PyrD | 0.2655 | 1 | 0.5 |
Loa Loa (eye worm) | hypothetical protein | 0.006 | 0 | 0.5 |
Echinococcus granulosus | dihydropyrimidine dehydrogenase NADP | 0.1037 | 0.3765 | 1 |
Activity type | Activity value | Assay description | Source | Reference |
---|---|---|---|---|
Potency (functional) | 3.5481 uM | PUBCHEM_BIOASSAY: qHTS for Inhibitors of Polymerase Iota. (Class of assay: confirmatory) [Related pubchem assays (depositor defined):AID588623] | ChEMBL. | No reference |
Potency (functional) | = 5.6234 um | PUBCHEM_BIOASSAY: qHTS Screen for Compounds that Selectively Target Cancer Cells with p53 Mutations: Cytotoxicity of p53ts Cells at the Nonpermissive Temperature. (Class of assay: confirmatory) | ChEMBL. | No reference |
Potency (functional) | 79.4328 uM | PUBCHEM_BIOASSAY: HTS for Inhibitors of HP1-beta Chromodomain Interactions with Methylated Histone Tails. (Class of assay: confirmatory) [Related pubchem assays (depositor defined):AID488962] | ChEMBL. | No reference |
Many chemical entities in TDR Targets come from high-throughput screenings with whole cells or tissue samples, and not all assayed compounds have been tested against a single a single target protein, probably because they get ruled out during screening process. Even if these compounds may have not been of interest in the original screening, they may come as interesting leads for other screening assays. Furthermore, we may be able to propose drug-target associations using chemical similarities and network patterns.